KAMPALA, Uganda — The U.S. Food and Drug Administration (FDA) has agreed to waive clinical efficacy testing requirements for two of Dei Biopharma’s cancer therapies, including pembrolizumab (Keytruda) and trastuzumab...
BRAMPTON, Ontario — Dr. Matthias Magoola, a Ugandan scientist and founder of Dei Biopharma Ltd., has been honored with the Lifetime Achievement Award at the 2025 Sankofa Royale Award Gala...
KAMPALA, UGANDA — Dei BioPharma Ltd announced on Tuesday that the U.S. Food and Drug Administration has accepted the development plan for two of its novel biological drugs, liraglutide and...
KAMPALA. Dr. Matthias Magoola, the Founder and Managing Director of Dei Biopharma Ltd, has been honoured with the prestigious "Faces of Science" Award in recognition of his groundbreaking contributions to...
KAMPALA – Dr. Matthias Magoola, the founder and Managing Director of Dei Biopharma Ltd, has published a major scientific paper in the internationally renowned peer-reviewed journal Cancers, offering fresh insights...
RNA-based cancer vaccines are a breakthrough treatment that trains the immune system to recognize and attack specific cancer cells. Recent clinical trials have shown impressive results, with one melanoma treatment...
